Alector to Participate in the Bank of America CNS Therapeutics Conference
Alector (Nasdaq: ALEC) announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025 at 2:25 pm ET.
Rhea-AI Summary
Alector (Nasdaq: ALEC) announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference on Monday, December 8, 2025 at 2:25 pm ET. A live webcast will be available on the company’s Investors > Events & Presentations page at http://investors.alector.com. A replay will be posted on the Alector website and will remain available for 90 days following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ALEC
In the Dec 2 session, ALEC declined 7.32%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- December 8, 2025
- Date of Bank of America CNS Therapeutics Conference fireside chat
- Start time
- 2:25 pm ET
- Scheduled time for the fireside chat webcast
- Replay period
- 90 days
- Length of time webcast replay remains available on company website
Historical Context
-
Announced fireside chat at Bank of America CNS Therapeutics Conference webcast.
-
Reported Q3 2025 results, ABC pipeline progress, cash runway and trial status.
-
Phase 3 latozinemab trial failed clinical endpoint; workforce cut and trial stops.
-
Announced virtual R&D event on PGRN franchise and ABC-enabled programs.
-
Planned presentations at three September healthcare investor conferences via webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET.
A webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.
About Alector
Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts:
Argot Partners (media)
David Rosen
(212) 600-1494
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.